Adenovirus serotype 5 (Ad5) is particularly common, and a vaccine vector based on an attenuated Ad5, developed by Merck, has already been tested as an HIV vaccine. Although Merck’s candidate succeeded in inducing CD8 T cell responses in a far greater proportion of recipients than any prior vector, in an efficacy study in gay men—named the STEP trial—it failed to protect against HIV infection and enhanced the risk of acquisition in a subset of participants (uncircumcised men with pre-existing antibodies against Ad5).
After 28 days, most participants had a four-fold increase in binding antibodies (35/36, 97% low-dose group; 34/36 (94%) middle-dose group, and 36/36, 100% in high-dose group), and half (18/36) of participants in the low- and middle-dose groups and three-quarters (27/36) of those in the high-dose group showed neutralising antibodies against SARS-CoV-2.
youyuanfun 发表评论于 2020-05-22 11:04:51
人家的葡萄总是酸的？！
十具 发表评论于 2020-05-22 11:00:38
Comments of NYT: "The vaccine reported today was created with an adenovirus called Ad5 that easily enters human cells. However, many people already have been exposed to Ad5, so there is concern that antibodies to it will be too common to allow the vaccine to work widely.The vaccine reported today was created with an adenovirus called Ad5 that easily enters human cells. However, many people already have been exposed to Ad5, so there is concern that antibodies to it will be too common to allow the vaccine to work widely."
十具 发表评论于 2020-05-22 10:52:15
"By day 28, half of the patients in the low- and middle-dose groups showed neutralizing antibodies compared with three-quarter of patients in the high-dose group."
十具 发表评论于 2020-05-22 10:47:55
CNBC reports "Coronavirus vaccine in China produces neutralizing antibodies in early-stage trial".
。。。At least one adverse reaction within the first 7 days after the vaccination was reported in 30 (83%) participants in the low dose group, 30 (83%) participants in the middle dose group, and 27 (75%) participants in the high dose group. The most common injection site adverse reaction was pain, which was reported in 58 (54%) vaccine recipients, and the most commonly reported systematic adverse reactions were fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]. 。。。。 Our findings suggest that the Ad5 vectored COVID-19 vaccine warrants further investigation.
